Study of SGN-40 in Patients With Relapsed Diffuse Large B-Cell Lymphoma
Status:
Completed
Trial end date:
2009-01-01
Target enrollment:
Participant gender:
Summary
This is a Phase II, open-label, multidose trial of SGN-40 designed to estimate objective
response rate and assess toxicity in patients with relapsed DLBCL.